Name: PT-141 Spray | 30mg | 30ml | Captide Labs
SKU: CPT-SPRY-PT141-30MG
Price: 129.99 USD
Availability: InStock

Description

Performance →·Cognitive →

PT-141 Research Spray | Bremelanotide & Melanocortin Receptor Agonist

Captide Labs PT-141 Spray delivers research-grade Bremelanotide in a pre-formulated, ready-to-use liquid spray format. Each 30ml bottle contains 30mg of PT-141 at greater than 98% purity, independently verified by HPLC-MS analysis and documented with a full Certificate of Analysis. Concentration is 1mg/ml, with each actuation delivering approximately 150–500mcg depending on application protocol.

PT-141 (CAS 189691-06-3, also known as Bremelanotide) is a brain-penetrant synthetic cyclic heptapeptide derived from α-MSH (alpha-melanocyte stimulating hormone). It functions as a broad melanocortin receptor agonist with documented activity at MC1R, MC3R, MC4R, and MC5R — with reported MC4R binding affinity of approximately 10 nM. PT-141 was approved by the FDA in June 2019 as Bremelanotide (Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of the few research peptides in the contemporary catalog with an approved clinical indication.

Research Specifications

Compound

PT-141 (Bremelanotide)

CAS Number

189691-06-3

Molecular Formula

C₅₀H₆₈N₁₄O₁₀

Molecular Weight

1025.18 g/mol

Chemical Class

Cyclic heptapeptide (α-MSH analogue)

Receptor Targets

MC1R / MC3R / MC4R / MC5R

MC4R Affinity

~10 nM (Ki, HEK-293)

Purity

>98% (HPLC-MS Verified)

Amino Acid Sequence

Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

Format

Liquid Spray

Concentration

1mg/ml

Bottle Volume

30ml

Total Peptide Content

30mg

Spray Delivery

150–500mcg per actuation

Testing Standard

ISO 17025 Accredited Lab

Storage

Refrigerate at 2–8°C. Do not freeze in liquid form. Use within 28–30 days of opening.

What is PT-141?

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II research. It is a brain-penetrant melanocortin receptor agonist with documented activity at multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R) — with particular research interest in its MC4R activity, since MC4R is expressed extensively in the hypothalamus and limbic system, brain regions involved in motivation, reward, and arousal signaling. Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally on vascular smooth muscle, PT-141 acts centrally on neural circuits, representing a mechanistically distinct approach to sexual function research.

PT-141 was originally derived from Melanotan II development as a candidate for sexual function applications. Early Phase 2 intranasal studies in men with erectile dysfunction demonstrated statistically significant pro-erectile effects, and subsequent development pivoted to female sexual dysfunction — culminating in FDA approval of Bremelanotide (Vyleesi) on June 21, 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It remains one of the few CNS-active research peptides with a fully approved clinical indication, and continues to be studied in mechanism-of-action research that probes the melanocortin system’s role in arousal, mood, and reward circuitry.

Research Overview

Areas of Active PT-141 Investigation

Melanocortin Receptor Pharmacology

PT-141 is used as a brain-penetrant agonist probe for melanocortin receptor subtypes in receptor pharmacology research. Reported MC4R binding affinity is approximately 10 nM by competitive binding in HEK-293 cells, with downstream cAMP accumulation confirming functional agonism. Researchers use PT-141 to map ligand-receptor selectivity, second-messenger cascades, and downstream gene expression effects across the MC1R/MC3R/MC4R/MC5R subtype family, providing a well-characterized tool for dissecting melanocortin system function in controlled in vitro assays and animal models.

CNS-Mediated Sexual Arousal & Desire Pathways

PT-141 has one of the most robust clinical evidence bases of any research peptide for sexual function. Phase 2 and Phase 3 clinical trials (RECONNECT-1 and RECONNECT-2) demonstrated significant improvements in desire scores and satisfying sexual events versus placebo in women with HSDD. Earlier Phase 2 intranasal studies in men with erectile dysfunction demonstrated pro-erectile effects at approximately 50 μg/kg, establishing PT-141’s relevance to both male and female sexual function research models — with the bulk of regulatory and mechanistic data drawn from approximately 3,500 human subjects across 43 completed clinical studies.

Dopaminergic Signaling & Reward Circuitry

PT-141’s CNS mechanism appears to involve dopaminergic activation in the medial preoptic area (MPOA) — a hypothalamic region central to sexual behavior in multiple species. Research has examined how MC4R activation in these regions generates arousal signals through dopaminergic projections, and how this intersects with the mesolimbic reward system. This makes PT-141 a useful tool for studying the neurological basis of sexual desire and its connection to broader motivational and reward signaling circuits.

Melanocortin System & Energy Homeostasis

Beyond sexual function, the melanocortin system — and MC4R in particular — plays a well-established role in energy balance, feeding behavior, and metabolic regulation. MC3R and MC4R are both expressed in the hypothalamus and are involved in food intake regulation. PT-141’s brain-penetrant pharmacology makes it a useful tool in studies examining melanocortin pathway contributions to energy homeostasis, body weight regulation, and the intersection of metabolic and reproductive signaling.

Intranasal Peptide Delivery Research

PT-141 has a particularly rich intranasal delivery research history — Palatin’s earliest Phase 2 work in men used intranasal Bremelanotide, demonstrating bioactive systemic concentrations through nasal mucosa absorption. While the approved Vyleesi product uses subcutaneous administration, the nasal route remains an active research delivery method for the compound. Researchers studying intranasal peptide delivery use PT-141 as a reference compound for nasal absorption kinetics, bioavailability comparison, and CNS access via the olfactory pathway.

Third-Party Certificate of Analysis

Every batch of PT-141 Spray is independently tested by an ISO 17025-accredited laboratory. View the full COA including identity confirmation, purity assay, heavy metals, and microbial results on the Captide Labs Lab Reports page.

View COA →

Frequently Asked Questions

What is PT-141 used for in research?

PT-141 is used in preclinical and clinical research to study melanocortin receptor pharmacology, CNS-mediated arousal and desire signaling, sexual dysfunction models, dopaminergic reward circuitry, and melanocortin system contributions to energy homeostasis. It is one of the few research peptides with a fully approved FDA indication — approved as Bremelanotide (Vyleesi) in June 2019 for hypoactive sexual desire disorder in premenopausal women — making it one of the most clinically validated CNS-active compounds in the research peptide catalog.

How does PT-141 differ from PDE5 inhibitors like Viagra?

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) act peripherally — they increase blood flow to genital tissue by inhibiting the phosphodiesterase enzyme that breaks down cGMP in vascular smooth muscle. PT-141 acts centrally, engaging melanocortin receptors (particularly MC4R) in the hypothalamus and limbic system to modulate the brain’s arousal and desire signaling pathways through downstream dopaminergic activation. This mechanistic distinction makes PT-141 a uniquely valuable research tool for studying the neurological basis of sexual function, independent of vascular mechanisms.

What is the concentration of this spray?

Each 30ml bottle contains 30mg of PT-141, yielding a concentration of 1mg/ml. Each actuation delivers 150–500mcg depending on the spray pump volume used. At 30mg total, this bottle provides substantially more peptide per unit than the 10mg vials typical in the research market — making it well-suited for extended or multi-dose research protocols.

What is the CAS number for PT-141?

The CAS number for PT-141 (Bremelanotide free base) is 189691-06-3. Its molecular formula is C₅₀H₆₈N₁₄O₁₀ with a molecular weight of 1025.18 g/mol. The acetate salt form (Bremelanotide acetate, as used in the approved Vyleesi product) has a separate CAS number of 1607799-13-2. PT-141 is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH.

How does PT-141 relate to Melanotan II?

PT-141 was derived from Melanotan II development. Melanotan II is a broader melanocortin agonist that strongly activates MC1R (responsible for skin pigmentation) along with MC3R, MC4R, and MC5R. PT-141 retains activity across the melanocortin receptor family (MC1R, MC3R, MC4R, MC5R) but with a refined profile that produced the pronounced pro-arousal signal observed in clinical development. The two compounds share α-MSH-derived cyclic peptide structure but differ in receptor binding selectivity and pharmacological profile.

Is PT-141 selective for MC4R?

No — PT-141 is a broad melanocortin agonist, not an MC4R-selective compound. It has documented activity across MC1R, MC3R, MC4R, and MC5R (the order of potency varies by source, but MC4R and MC1R are typically the highest-affinity targets). For MC4R-selective research applications, setmelanotide is the more appropriate selective tool compound. PT-141’s broader receptor profile is what differentiates its in vivo pharmacology — and is also why early clinical research observed both arousal (largely MC4R-mediated) and incidental skin pigmentation effects (MC1R-mediated) at higher doses.

How should PT-141 Spray be stored?

Store PT-141 Spray refrigerated at 2–8°C. Do not freeze once in liquid form, as freeze-thaw cycling can compromise peptide integrity. Keep away from direct light and heat. Once opened, use within 28–30 days for best results. The cyclic peptide structure of PT-141 contributes to its stability relative to linear peptides, but cold storage is still recommended at all times to preserve maximum potency over the life of the bottle.

For research use only. Not for human consumption, veterinary use, or food/agricultural applications. While Bremelanotide is FDA-approved as Vyleesi (a separate, distinct pharmaceutical product), this research-grade material is not evaluated or approved by the FDA. Not intended to diagnose, treat, cure, or prevent any condition. All purchases are made with the understanding that this compound is strictly for in-vitro research and laboratory use. See the full Research Use Only (RUO) Policy.

FDA Disclosure & Intended Use

FDA Disclosure: The statements on this website and the products sold herein have not been evaluated by the U.S. Food and Drug Administration (FDA). These products are not intended to diagnose, treat, cure, or prevent any disease. Products sold are for Research Use Only and are not for human or animal use.

Intended Purpose: Products sold on this site are intended solely for basic laboratory research, pharmaceutical research, or the development of new tests. They are not intended for diagnostic, therapeutic, or clinical use.

Storage Instructions

Handling and Storage Tips:

Keep peptides cold and away from light once received.
For short-term use (days to weeks), refrigeration at 4°C (39°F) is acceptable.
Lyophilized peptides are typically stable at room temperature for several weeks, making it suitable for moderate-term storage.
For long-term storage (months to years), it’s best to freeze peptides at -80°C (-112°F). Freezing optimally preserves peptide stability for extended periods.

Reviews (0)

Thanks for your review!

Your feedback helps us improve our service.

error

Please Insert Review Title

Please Insert Review Feedback

Please Insert Your Email

Yes

Research Use Only (RUO) Policy

"RUO" is an abbreviation for Research Use Only. It is a designation used primarily by the FDA (Food and Drug Administration) for products, often in vitro diagnostic (IVD) components like reagents or instruments, that are in the laboratory research phase of development and are not intended for clinical diagnostic use.

READ MORE